AND017 vs Enarodustat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

AND017

Developed by Kind Pharmaceuticals

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT05265325 · Phase 2 · completed

The study was randomized, triple-blind, and active-controlled, with 175 participants assigned to AND017 or standard erythropoiesis-stimulating therapy. However, the registry does not report whether the primary endpoints—adverse-event incidence and mean hemoglobin change at Week 6—were met, so the findings cannot be judged as demonstrating a positive effect.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07494409 (registry estimate)

No aligned efficacy figure on record for this race.

Enarodustat

Marketed by Shionogi and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT04027517 · Phase 3 · completed

The trial was randomized and actively controlled with 172 participants, but it was open-label and used hemoglobin, a laboratory surrogate, as its primary endpoint. Because no primary endpoint results or statistical comparison are available, the study provides limited evidence rather than demonstrating a positive or negative treatment effect.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: June 2027 · NCT07079579 (registry estimate)

Reported efficacy

Difference in mean Hb concentration levels from baseline at weeks 7-9 (Baseline and week 7-9): Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001 (met)

Result source: NCT06016036

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAND017Enarodustat
Kidney composite outcome—Trial running · NCT07487727—Not posted · NCT04027517
UACR, % change—Trial running · NCT07487727—Not posted · NCT04027517
eGFR slope—Trial running · NCT07487727—Not posted · NCT04027517
Haemoglobin, change—Trial running · NCT07487727—Not posted · NCT04027517

Kidney composite outcome

AND017
—Trial running · NCT07487727
Enarodustat
—Not posted · NCT04027517

UACR, % change

AND017
—Trial running · NCT07487727
Enarodustat
—Not posted · NCT04027517

eGFR slope

AND017
—Trial running · NCT07487727
Enarodustat
—Not posted · NCT04027517

Haemoglobin, change

AND017
—Trial running · NCT07487727
Enarodustat
—Not posted · NCT04027517
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AND017: no structured comparison results are available for Chronic Kidney Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Enarodustat
평가기간 중 투여군간 차이 [95% 신뢰구간] -0.19 [-0.46, 0.08] (이 약 투여군 N=57 평가기간 중 Hb 농도 평균 10.65 g/dL, 다베포에틴 알파 투여군 N=67 10.83 g/dL; 베이스라인 10.73 vs 10.68 g/dL; 비열등성 마진 -1.0 g/dL) NCT04027517 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001 NCT06016036 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AND017's landscape · Enarodustat's landscape